GSA Capital Partners LLP Has $230,000 Stake in Biohaven Ltd. (NYSE:BHVN)

GSA Capital Partners LLP cut its stake in Biohaven Ltd. (NYSE:BHVN) by 70.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,609 shares of the company’s stock after selling 11,124 shares during the period. GSA Capital Partners LLP’s holdings in Biohaven were worth $230,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Biohaven by 280.5% during the first quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after acquiring an additional 4,650,702 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Biohaven by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock worth $183,050,000 after purchasing an additional 212,699 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Biohaven by 181.4% in the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock valued at $78,028,000 after buying an additional 1,449,000 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Biohaven by 74.8% in the second quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock valued at $48,489,000 after buying an additional 597,705 shares in the last quarter. Finally, ARS Investment Partners LLC increased its holdings in Biohaven by 47.8% during the second quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock worth $32,645,000 after buying an additional 304,141 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Insider Activity at Biohaven

In related news, Director John W. Childs acquired 21,052 shares of Biohaven stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average price of $47.50 per share, with a total value of $999,970.00. Following the transaction, the director now directly owns 21,052 shares in the company, valued at $999,970. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gregory Bailey bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The shares were bought at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the transaction, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. This trade represents a 0.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $59.00 price objective on shares of Biohaven in a research note on Thursday, November 14th. Sanford C. Bernstein lifted their price objective on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Leerink Partners increased their price objective on shares of Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Royal Bank of Canada reduced their target price on shares of Biohaven from $68.00 to $66.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Finally, Jefferies Financial Group assumed coverage on shares of Biohaven in a report on Monday, September 16th. They issued a “buy” rating and a $57.00 price target on the stock. Thirteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $63.42.

Biohaven Stock Performance

NYSE BHVN opened at $45.59 on Monday. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The stock has a market cap of $4.61 billion, a PE ratio of -4.88 and a beta of 1.31. The firm’s fifty day moving average price is $49.10 and its two-hundred day moving average price is $41.10.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, sell-side analysts predict that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.